SRSusanna Ranta

Susanna Ranta

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Susanna Ranta has a total of 260 co-authors. Here are the top co-authors by number of shared publications:

  • Arja Harila-Saari

    Department of Women's and Children's Health Uppsala University Uppsala Sweden

    10 shared publications
  • Mats Heyman

    Unit for Pediatric Oncology Department of Women's and Children's Health Karolinska Institutet Stockholm Sweden

    10 shared publications
  • Nadine Gretenkort Andersson

    Center For Thrombosis and Haemostasis Sweden and Department of Clinical Sciences and Paediatrics Skåne University Hospital, Malmö, Lund University Lund Sweden

    7 shared publications
  • Johan E. Svahn

    Department of Paediatric Oncology, Skåne University Hospital Lund University Lund Sweden

    6 shared publications
  • Jonas Abrahamsson

    Department of Pediatrics Institute of Clinical Sciences Sahlgrenska Academy University of Gothenburg Gothenburg Sweden

    6 shared publications
  • Lisa Törnudd

    Division of Children's and Women's Health, Department of Biomedical and Clinical Sciences Linköping University Linköping Sweden

    6 shared publications

Latest Publications

  • Open Access

    Early Toxicity in Childhood Acute Lymphoblastic Leukemia: A Comparison of NOPHO ALL2008 and ALLTogether Protocols in Sweden

    by Johannes Fermér, Hannah van Bunningen, Otto Zhou, Jonas Abrahamsson, Magnus Borssen, Isabella Donnér, Mats Heyman, Anna Sällfors Holmqvist, Anders Valind, Hartmut Vogt, et al.

    Background: The European ALLTogether protocol for childhood acute lymphoblastic leukemia, initiated in Sweden 2019, introduced earlier asparaginase during induction, dexamethasone instead of prednisone for all patients, and omitted anthracyclines from low‐risk induction to reduce treatment‐related toxicity. Consolidation‐1 was based on the Induction 1B‐phase developed by the BFM‐group, replacing mercaptopurine, methotrexate, and asparaginase used in the previous NOPHO ALL2008 protocol, ALL2008. Following implementation, early treatment toxicity was considered unacceptably high, prompting a protocol amendment. We compared the prevalence of 14 predefined toxicities, the number of inpatient days, and weight changes during induction and consolidation‐1 between the two protocols. Methods: We conducted a population‐based cohort study in Sweden, reviewing patient records from 117 children treated under ALLTogether protocol and 234 matched controls under ALL2008 protocol. Results: The mean number of toxicities per patient was similar between the protocols (2.5 [290/117] vs. 2.3 [547/234]). ALLTogether cohort had significantly greater weight gain, with over 50% experiencing a > 10% increase ( p < 0.01). Hyperglycemia (OR 5.17, 95% CI 1.93–13.82) and osteonecrosis (3.4% vs. 0%, p = 0.012) were more common, while liver dysfunction (0.59, 0.38–0.93) was less frequent in the ALLTogether protocol. The number of inpatient days was similar across protocols, except for the initial hospitalization, which was longer in ALLTogether (median 11 vs. 7 days, p < 0.01). Conclusions: The early introduction of asparaginase likely contributed to increased weight gain, hyperglycemia, and osteonecrosis. While overall toxicity burden remained similar between protocols, the shift in toxicity profile may explain the perception of increased early toxicity during treatment with the ALLTogether protocol. Trial Registration: ClinicalTrials.gov identifier: NCT03911128; EudraCT numbers: 2018‐001795‐38 and 2008‐003235‐20

  • Open Access

    Infectious Complications During Early Treatment of Childhood Acute Lymphoblastic Leukemia—A Comparison Between the ALLTogether and NOPHO ALL‐2008 Protocols

    by Hannah van Bunningen, Johannes Fermér, Arja Harila, Susanna Ranta, Isabella Donnér, Anne Wretman, Hartmut Vogt, Anna Sällfors Holmqvist, Anders Valind, Ludvig Henriksson, et al.

    Introduction: Infection remains the most common treatment‐related toxicity of childhood ALL, emphasizing the need to identify patients at risk and to tailor treatment strategies accordingly. Aims: The primary aim was to compare infectious toxicity during early treatment for childhood ALL following the ALLTogether and NOPHO ALL‐2008 (ALL‐2008) protocols, and second, to identify risk factors for infectious toxicity. Methods: A national retrospective matched cohort study was conducted, including 345 patients aged 1–17 years diagnosed with ALL and treated in Sweden according to the ALLTogether or ALL‐2008 protocols. Nonparametric tests were used to compare infectious outcomes between protocols, and regression modeling was used to identify risk factors of the infectious outcomes. Results: Treatment following ALL‐2008 showed higher infectious toxicity during induction, whereas treatment following ALLTogether showed increased infectious toxicity during consolidation 1. Overall, treatment according to ALL‐2008 was associated with a higher incidence of infections. Anthracycline use and young age (1–9 years) were associated with both higher infectious incidence and more severe infectious complications. Dexamethasone was associated with both lower incidence and lower severity of infectious complications as compared to prednisone. Conclusions: A notable shift in the timing of infectious toxicity was observed between the two treatment protocols. Risk factors for infectious toxicity during early treatment include anthracycline use and young age. Dexamethasone as an induction steroid was associated with lower infectious burden, although its effect is difficult to isolate from the simultaneous anthracycline effect. The findings suggest that treatment composition plays a central role in determining both the extent and timing of infectious complications.


  • Differences Between Sweden and Greece in Joint Outcomes Assessed by Ultrasound in Adolescents With Severe Haemophilia on Prophylaxis: Data From the PedNet Registry

    by Aikaterini Michalopoulou, Susanna Ranta, Nadine G. Andersson, Kathelijn Fischer, Marloes de Kovel, Elsbeth de Boer‐Verdonk, Jayashree Motwani, Gili Kenet, Helen Pergantou

    Introduction: Different strategies in prophylaxis for haemophilia among countries may affect long‐term outcome. Aim: The aim of this study is to compare joint health in persons with severe haemophilia (PwSH) between Sweden and Greece, based on different approaches on prophylaxis initiation and management. Methods: Data were extracted from the PedNet Registry, which collects patient data prospectively, regarding measures on treatment and joint health using Haemophilia Joint Health Score (HJHS) and Haemophilia Early Arthropathy Detection with Ultrasound (HEAD‐US). Results: Sixty‐one Swedish and 51 Greek PwSH (aged ≥ 10–18 years) were included. Swedish adolescents were diagnosed at earlier age (0.53 vs. 0.77 years in Greece, p < 0.01). At prophylaxis initiation {earlier in Sweden ( p < 0.01)}, dose regimens were more intense and escalation to full prophylaxis was reached earlier in Sweden. Median age at the last HEAD‐US was 15.82 versus 14.07 years and at the last HJHS: 15.26 versus 15.86 years, for Sweden and Greece, respectively. Swedish and Greek PwSH had similar median total HJHS: 1.5 versus 1.0, respectively, p = 0.38. Based on HEAD‐US, signs of synovitis were less frequent in Sweden for ankles (31.1% vs. 72.2%; p < 0.01), knees (11.1% vs. 44.4%, p < 0.01) and elbows (8.9% vs. 27.8%, p < 0.05). Bone/cartilage abnormalities were also less frequent in Swedish patients (ankles: 11.1% vs. 30.6%; p < 0.05, knees: 6.7% vs. 11.1%; p = 0.69, elbows: 8.9% vs. 19.4%; p = 0.20). Conclusion: Although adolescent PwSH clinically have good joint health in both countries, differences were detected by HEAD‐US, with earlier prophylaxis in Sweden being associated with better joint outcomes.


  • Open Access

    Benchmarking prophylaxis with factor concentrates: reference data on annualized bleeding rates in children with severe hemophilia

    by Susanna Ranta, Marloes De Kovel, Martin Olivieri, Kathelijn Fischer, Giancarlo Castaman, Christoph Königs, Johannes Oldenburg, Helen Pergantou, Christoph Male, Marijke H. Van Den Berg


  • Blood Group O Does Not Increase the Risk of Inhibitors in Severe Haemophilia A: Data from the PedNet Study Group

    by Marloes de Kovel, Aimée-Claire van Haaster, Manuel Carcao, Susanna Ranta, Heidi Glosli, Georges E Rivard, Gili Kenet, Karin Kurnik, Christel Van Geet, Manuela Carvalho, et al.

    Introduction: Inhibitor development against factor VIII (FVIII) is the most common complication of hemophilia A replacement therapy. One of the variables considered to influence inhibitor development is the ABO blood group. Patients with blood group O have, on average, a 30%–40% lower endogenous von Willebrand factor (VWF) concentration. It has been postulated that VWF levels influence inhibitor development. The objective of this study was to investigate the inhibitor risk in patients with severe hemophilia A comparing those with blood group O with those with non‐O blood groups. Methods: The study population consisted of children with severe hemophilia A, born between 2000 and 2020, who reached 50 FVIII exposure days in the PedNet registry. Inhibitors were considered to be clinically relevant when at least two consecutive measurements were tested positive. Results: Routine testing of blood groups varied between centres: Out of 1172 patients with severe hemophilia A, blood group status was known in 759 patients (65.8%). The relative risk of inhibitor development for blood group O in comparison to non‐O was 1.04 (95% CI: 0.7–1.7). Conclusion: In the PedNet cohort, blood group O did not increase the risk of inhibitors in previously untreated children with severe hemophilia A. Trial Registration: PedNet Registry; clinicaltrials.gov identifier: NCT02979119


  • A survey on clinical practice in monitoring and management of bleeding in children with haemophilia A on emicizumab prophylaxis in the PedNet centres

    by Susanna Ranta, Ester Zapotocka, Nadine G. Andersson, Kathelijn Fischer, Gili Kenet, Marloes de Kovel, Christoph Königs, Veerle Labarque, Christoph Male, Martin Olivieri, et al.


  • Open Access

    Haemostasis during early treatment of childhood acute lymphoblastic leukaemia with the ALLTogether protocol

    by Johannes Fermér, Jonas Jalnäs, Jonas Abrahamsson, Magnus Borssen, Isabella Donnér, Ludvig Henriksson, Mats Heyman, Anna Sällfors Holmqvist, Anders Valind, Hartmut Vogt, et al.

  • Open Access

    Symptomatic osteonecrosis in children treated for Hodgkin lymphoma: A population‐based study in Sweden, Finland, and Denmark

    by Mia Giertz, Henri Aarnivala, Sascha Wilk Michelsen, Caroline Björklund, Annika Englund, Marika Grönroos, Lisa Lyngsie Hjalgrim, Pasi Huttunen, Tuukka Niinimäki, Eva Penno, et al.

    Background: Osteonecrosis (ON) is a potentially disabling skeletal complication of cancer treatment. Although symptomatic osteonecrosis (sON) is well‐known in acute lymphoblastic leukemia (ALL), with an incidence around 6%, studies on sON in pediatric Hodgkin lymphoma (HL) are scarce. The aim of this study was to examine the incidence, risk factors, and outcome of sON in children treated for HL.Procedure: A total of 490 children under 18, diagnosed with HL between 2005 and 2019 in Sweden, Finland, and Denmark were eligible for the study. Data on patient characteristics, HL treatment, and development of sON were collected from patients’ medical records. Magnetic resonance imaging scans were used to establish ON diagnosis and grade ON according to the Niinimäki grading system.Results: Cumulative 2‐year incidence of sON among the 489 included patients was 5.5% (n = 30). The risk for developing sON was higher for those with older age (odds ratio [OR] 1.25, 95% confidence interval [CI]: 1.05–1.49, p < .010), female sex (OR 4.45, CI 1.87–10.58, p < .001), high total cumulative glucocorticoid (GC) doses (OR 1.76, 95% CI: 1.21‐2.56, p = 0.003), and advanced HL (OR 2.19, 95% CI: 1.03‐4.65, p = .042). Four (13.3%) patients underwent major surgical procedures and 13 (43.3%) had persistent symptoms due to ON at follow‐up.Conclusions: This study shows that sON is as common in pediatric HL as in pediatric ALL, with risk factors such as older age, female sex, high cumulative GC doses, and advanced HL. Future HL protocol development should aim to reduce the burden of ON by modifying GC treatment.


  • Open Access

    Overcoming Brigatinib Resistance with Lorlatinib in Pediatric ALK Positive Anaplastic Large Cell Lymphoma with Acquired ALK p.F1174V Mutation – a Case Report

    by Sandra Wessman, Nina Mogensen, Susanna Ranta, Leonie Saft, Tatiana von Bahr Greenwood, Bianca Tesi, Teresita Díaz De Ståhl, Fredrik Baecklund

  • Open Access

    Radiological follow‐up of osteonecrosis lesions in children and adolescents with Hodgkin lymphoma

    by Henri Aarnivala, Mia Giertz, Sascha Wilk Michelsen, Caroline Björklund, Annika Englund, Marika Grönroos, Lisa Lyngsie Hjalgrim, Pasi Huttunen, Tuukka Niinimäki, Eva Penno, et al.

    Summary: Osteonecrosis (ON) is a common complication of glucocorticoid‐based Hodgkin lymphoma (HL) treatment, but the natural evolution and prognosis of ON lesions remain poorly understood. We describe the radiological evolution of ON lesions identified in a Nordic population‐based cohort of paediatric HL patients. Magnetic resonance images of suspected ON lesions were centrally reviewed to confirm ON diagnosis and grade the ON lesions according to the Niinimäki classification. The study included 202 ON lesions in 46 patients, of which 77 were joint lesions. Follow‐up images were available for 146/202 lesions, with a mean follow‐up time of 28 months. During follow‐up, 71% of the lesions remained stable, 26% improved or resolved, and 3% progressed. A higher ON grade at diagnosis was associated with a lower likelihood of spontaneous resolution. The likelihood for resolution of ON decreased by 50% for each year of added patient age, when adjusted for sex, ON location, and symptoms. Hip ON showed less spontaneous improvement compared with other joints, and the risk for surgery was 13‐fold in hip ON. Grades 3–4 joint ON has the potential to either progress or resolve, warranting follow‐up in patients with severe symptoms. Research on secondary prevention should be directed at grade 3–4 joint ON.